Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Multiplex Screening for Interacting Compounds in Paediatric Acute Myeloid Leukaemia.

International journal of molecular sciences - 21 Sept 2021

Cairns Lauren V, Lappin Katrina M, Mutch Alexander, Ali Ahlam, Matchett Kyle B, Mills Ken I

Abstract excerpt

Paediatric acute myeloid leukaemia (AML) is a heterogeneous disease characterised by the malignant transformation of myeloid precursor cells with impaired differentiation. Standard therapy for paediatric AML has remained largely unchanged for over four decades and, combined with inadequate understanding of the biology of paediatric AML, has limited the progress of targeted therapies in this cohort. In recent...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Blotting, Western

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Cell Line

Share to Cell Line, Tumor

Share to Cell Survival

Share to Drug Repositioning

Share to Flow Cytometry

Share to Leukemia, Myeloid, Acute

Source

Open in PubMed Open full text

Identifiers

PMID: 34576326
DOI: 10.3390/ijms221810163
PMCID: PMC8468645

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Multiplex Screening for Interacting Compounds in Paediatric Acute Myeloid Leukaemia.PMID 34576326Read ↗

Pharmacogenomic Profiling of Pediatric Acute Myeloid Leukemia to Identify Therapeutic Vulnerabilities and Inform Functional Precision MedicineSemantic proximity Read ↗

Integrative Multiomics and Drug Sensitivity Profiling Reveal Potential Biomarkers and Therapeutic Strategies in Pediatric Solid Tumors.Semantic proximity Read ↗

An in vivo CRISPR screening platform for prioritizing therapeutic targets in AMLSemantic proximity Read ↗

Patient-tailored design of AML cell subpopulation-selective drug combinationsSemantic proximity Read ↗

Direct targeted therapy for MLL‐fusion‐driven high‐risk acute leukaemiasSemantic proximity Read ↗

Pharmacogenomics in pediatric leukemia.Semantic proximity Read ↗

Genome-wide CRISPR/Cas9 screen identifies etoposide response modulators associated with clinical outcomes in pediatric AMLSemantic proximity Read ↗

Leukemic stem cell signatures identify novel therapeutics targeting acute myeloid leukemiaSemantic proximity Read ↗

Methods for High-Throughput Drug Combination Screening and Synergy ScoringSemantic proximity Read ↗

Artificial intelligence platform, RADR®, aids in the discovery of DNA damaging agent for the ultra-rare cancer Atypical Teratoid Rhabdoid TumorsSemantic proximity Read ↗

“PBT-SCREEN”, a high-throughput screening platform to identify new therapeutic agents for Medulloblastoma Group 3Semantic proximity Read ↗

compaRe, an ultra-fast and robust suite for multiparametric screening, identifies phenotypic drug responses in acute myeloid leukemiaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.